Developer docs
API playgroundTry for free, no card

Search company profiles

Marius Pharmaceuticals

Full company profile

uuid0000xya

Namestring
Marius Pharmaceuticals
Legal namestring
Marius Pharmaceuticals, LLC
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Marius Pharmaceuticals is a privately held, Raleigh, North Carolina-based specialty biopharmaceutical company (Delaware LLC) founded in 2015 that develops and commercializes treatments for testosterone deficiency and related hormone health conditions. Its core product is KYZATREX (testosterone undecanoate), an FDA-approved oral softgel testosterone replacement therapy launched in August 2022 in 100mg, 150mg, and 200mg dosage strengths. The proprietary formulation utilizes a phytosterol-based lymphatic absorption delivery system that bypasses first-pass liver metabolism, distinguishing it from injectable and topical alternatives; twice-daily dosing mimics the natural diurnal rhythm of endogenous testosterone, and clinical data show 88-96% of patients achieving normal testosterone levels at Day 90 with a low hypertension adverse event rate of 2-2.6%.

The company makes money primarily through direct-to-consumer pharmaceutical product sales of KYZATREX at approximately $170 per month without insurance coverage, supplemented by licensing and distribution partnerships for international markets (Hikma for Canada, Smartway for global early access, Numan for UK). Its go-to-market combines DTC e-commerce, telehealth platform distribution (Hims & Hers, The Vitamin Shoppe's Whole Health Rx), specialty pharmacy networks, men's health clinics (Gameday Men's Health), and government channels (Department of Veterans Affairs). Supporting the commercial effort is the ReThink Testosterone disease-state awareness initiative and disease-state campaigns targeting men with hypogonadism, metabolic comorbidities, Klinefelter's syndrome, and veterans, with active FDA regulatory advocacy that contributed to the February 2025 removal of the cardiovascular boxed warning on testosterone products.

The company is pursuing additional growth through geographic expansion (Canada, UK), indication expansion (women's health, older men 65-80, GLP-1 co-therapy muscle preservation), and a recently announced Marius AI initiative launched in May 2026 that positions the firm as what it calls the first AI-native pharmaceutical company. The IP portfolio comprises six U.S. patents with coverage extending to 2040 plus international grants across the EU, Canada, China, Taiwan, Japan, and New Zealand. The company is led by founder Himanshu H. Shah (Executive Chairman) and Shalin Shah (CEO), with Amit Shah as COO and Om Dhingra as Vice Chairman, and operates with 11-50 employees.

Short descriptiontext

Marius Pharmaceuticals is a Raleigh-based specialty biopharmaceutical company that develops and commercializes KYZATREX, the first FDA-approved oral testosterone undecanoate therapy, selling primarily direct-to-consumer at ~$170/month and through telehealth and specialty pharmacy partners to men with hypogonadism.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRaleigh, United States
HQ citystring
Raleigh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
testosterone replacement therapy, oral testosterone medication, men's hormone therapy, biopharmaceutical products, FDA-approved pharmaceuticals
Industry1 code
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Testosterone Replacement Therapy
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Direct-to-consumer and partner-distributed sales of KYZATREX prescription medication. Launched in 2023 as a direct-to-consumer product without insurance coverage at approximately $170 per month.

medcitynews.com
2Licensing and Distribution Partnerships
TypeLicensing Royalties
Description

International licensing agreements such as the Hikma Pharmaceuticals licensing agreement for Canadian market and regional partnerships for global expansion.

nasdaq.com
3International Early Access Program
TypeLicensing Royalties
Description

Partnership with Smartway Pharmaceuticals for exclusive Early Access Provider arrangement in all countries outside the USA.

mariuspharma.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels9 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Others
Pricing details1 tier
1Monthly prescription at approximately $170 per month
ModelSubscriptionBilling cadenceMonthly
Notes

KYZATREX priced at approximately $170 per month as a direct-to-consumer product without insurance coverage. Available in three dosage strengths: 100mg, 150mg, and 200mg.

medcitynews.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1KYZATREX
Description

FDA-approved oral testosterone replacement therapy (testosterone undecanoate) CIII capsules for adult men with low testosterone levels.

mariuspharma.com
+1 more record
Core offering1 text field

Marius Pharmaceuticals develops and sells KYZATREX (testosterone undecanoate), an FDA-approved oral testosterone replacement therapy in softgel capsule form for adult men with low or no testosterone due to certain medical conditions. The proprietary formulation is absorbed via the lymphatic system to bypass first-pass liver metabolism and is administered twice daily in 100mg, 150mg, and 200mg dosages. The company also distributes the product through telehealth partnerships, retail health channels, specialty pharmacies, and international licensing agreements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 88-96% of patients achieved normal testosterone levels at Day 90
+4 more records
Product overview1 text field

Marius Pharmaceuticals is a specialty pharmaceutical company focused on testosterone replacement therapy. The company's primary product is KYZATREX (testosterone undecanoate), an FDA-approved oral softgel capsule TRT launched in August 2022. The company operates alongside ReThink Testosterone, a companion disease-state awareness initiative that educates patients about testosterone deficiency and treatment options. The company has expanded internationally with Health Canada approval and is pursuing AI-native capabilities through Marius AI.

Product and service2 records
1KYZATREX (testosterone undecanoate)
CategoryOral testosterone replacement therapy
Description

KYZATREX is an FDA-approved oral testosterone replacement therapy (TRT) in softgel capsule form, absorbed primarily via the lymphatic system to avoid liver toxicity. It is indicated for adult men with low or no testosterone due to certain medical conditions, administered twice daily with food in 100mg, 150mg, and 200mg dosages.

2Marius AI
CategoryAI-driven pharmaceutical technology
Description

Marius AI is an AI-native pharmaceutical initiative launched by Marius Pharmaceuticals, positioning the company as the first AI-native pharmaceutical company.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-05
Description

Licensing agreement for KYZATREX (testosterone undecanoate) CIII capsules in Canada. Enables Marius to expand market beyond the United States following Health Canada approval.

Strategic tierCoreTypeOthersAnnounced on2025-12-04
Description

CEO Shalin Shah invited to speak at landmark FDA Expert Panel on Testosterone Replacement Therapy for Men scheduled December 10, 2025. Significant regulatory engagement driving labeling updates.

3All-Female Advisory Board (Women's Health)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-05
Description

Formation of all-female advisory board including medical experts in urology, gynecology, longevity, and regenerative medicine to guide testosterone research for women, especially post-menopause.

mariuspharma.com
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-09-10
Description

Marius Pharmaceuticals and Hims & Hers collaboration to expand access to KYZATREX, the first FDA-approved oral testosterone therapy offered on the Hims & Hers platform. This partnership enables direct-to-consumer access through the Hims & Hers telehealth platform serving nearly 2.5 million subscribers.

5Major Academic Medical Center
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-03-03
Description

Partnership with major academic medical center on education and research efforts for oral testosterone, supporting clinical development and medical education.

mariuspharma.com
6US Specialists Management, LLC (USSM)
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-01-14
Description

Partnership with USSM through affiliated urologic in-office dispensaries, expanding specialty pharmacy distribution network.

mariuspharma.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-12-03
Description

Distribution expansion collaboration with Gameday Men's Health, providing access through their men's health clinic network.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-09-25
Description

Collaborative GLP-1 comparison study in male patients. Partnership to study KYZATREX's ability to prevent muscle loss from Wegovy ( GLP-1 medications) with 40% of weight loss being lean muscle.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-09-18
Description

Partnership with UK-based Numan to combat testosterone deficiency with KYZATREX. Expands access to men in the UK market.

10The Vitamin Shoppe
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-09-03
Description

Partnership to offer KYZATREX through The Vitamin Shoppe's Whole Health Rx telehealth platform powered by WellSync. Expands access to millions of American men experiencing testosterone deficiency through retail wellness channel.

mariuspharma.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-09-03
Description

Technology partner powering The Vitamin Shoppe's Whole Health Rx telehealth platform. Provides virtual care platform connecting patients with licensed healthcare providers in real time.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-08-10
Description

Smartway appointed as exclusive Early Access Provider for KYZATREX in all countries outside the USA. Smartway provides early access, compassionate use, and named patient supply services with hubs across UK, EU, Middle East, USA, and India.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Antares (now part of Halozyme) developed Tlando, an oral testosterone undecanoate product directly competing with KYZATREX in the same oral TRT category. Both companies target men with hypogonadism through similar regulatory pathways and compete for the same prescriber base.

TypeDirect peer
Description

Tolmar commercializes Jatenzo, another FDA-approved oral testosterone undecanoate and the closest direct competitor to KYZATREX. Both products use lymphatic absorption to avoid liver toxicity and compete for oral TRT market share.

TypeDirect peer
Description

Clarus Therapeutics developed Jatenzo (originally) and remains focused on oral testosterone therapies, directly competing with KYZATREX in the oral TRT space. Similar specialty pharma profile targeting hypogonadism.

4Acerus Pharmaceuticals
TypeEmerging player
Description

Acerus markets Natesto, a nasal testosterone replacement therapy, competing with KYZATREX for the same hypogonadism patient population through a differentiated non-oral delivery route. Similar specialty men's health focus.

TypeBroad incumbent
Description

AbbVie markets AndroGel, the legacy topical testosterone gel that has historically dominated the TRT market. While not a direct oral competitor, it serves the same hypogonadism patients and represents the standard-of-care Marius is displacing.

TypeBroad incumbent
Description

Endo markets Aveed (testosterone undecanoate injection), an injectable testosterone undecanoate product. Operates in the same testosterone replacement therapy market and competes for the same hypogonadism patient base.

TypeBroad incumbent
Description

Upsher-Smith markets Testim, a topical testosterone gel competing for hypogonadism patients. Specialty pharma with overlapping men's health franchise and similar commercial-stage profile.

TypeRegional player
Description

Besins manufactures AndroGel outside the US and other testosterone products globally, including in Europe and Asia. Comparable hormone therapy specialty pharma that Marius could eventually partner with or compete against in international markets.

TypeOthers
Description

Hims & Hers is both a partner and adjacent player; it offers competing men's health treatments including branded and generic testosterone therapies through its telehealth platform. Comparable as a DTC men's health channel rather than a direct therapeutic competitor.

TypeOthers
Description

Hikma is the Canadian licensing partner for KYZATREX and a broad specialty/generic pharmaceutical company with overlapping men's health and endocrinology portfolios. Comparable as a specialty pharma distributor and adjacent therapeutic category player.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Marius Pharmaceuticals

Testosterone Replacement Therapymariuspharma.com

Marius Pharmaceuticals is a Raleigh-based specialty biopharmaceutical company that develops and commercializes KYZATREX, the first FDA-approved oral testosterone undecanoate therapy, selling primarily direct-to-consumer at ~$170/month and through telehealth and specialty pharmacy partners to men with hypogonadism.

What Marius Pharmaceuticals does

Marius Pharmaceuticals is a privately held, Raleigh, North Carolina-based specialty biopharmaceutical company (Delaware LLC) founded in 2015 that develops and commercializes treatments for testosterone deficiency and related hormone health conditions. Its core product is KYZATREX (testosterone undecanoate), an FDA-approved oral softgel testosterone replacement therapy launched in August 2022 in 100mg, 150mg, and 200mg dosage strengths. The proprietary formulation utilizes a phytosterol-based lymphatic absorption delivery system that bypasses first-pass liver metabolism, distinguishing it from injectable and topical alternatives; twice-daily dosing mimics the natural diurnal rhythm of endogenous testosterone, and clinical data show 88-96% of patients achieving normal testosterone levels at Day 90 with a low hypertension adverse event rate of 2-2.6%.

The company makes money primarily through direct-to-consumer pharmaceutical product sales of KYZATREX at approximately $170 per month without insurance coverage, supplemented by licensing and distribution partnerships for international markets (Hikma for Canada, Smartway for global early access, Numan for UK). Its go-to-market combines DTC e-commerce, telehealth platform distribution (Hims & Hers, The Vitamin Shoppe's Whole Health Rx), specialty pharmacy networks, men's health clinics (Gameday Men's Health), and government channels (Department of Veterans Affairs). Supporting the commercial effort is the ReThink Testosterone disease-state awareness initiative and disease-state campaigns targeting men with hypogonadism, metabolic comorbidities, Klinefelter's syndrome, and veterans, with active FDA regulatory advocacy that contributed to the February 2025 removal of the cardiovascular boxed warning on testosterone products.

The company is pursuing additional growth through geographic expansion (Canada, UK), indication expansion (women's health, older men 65-80, GLP-1 co-therapy muscle preservation), and a recently announced Marius AI initiative launched in May 2026 that positions the firm as what it calls the first AI-native pharmaceutical company. The IP portfolio comprises six U.S. patents with coverage extending to 2040 plus international grants across the EU, Canada, China, Taiwan, Japan, and New Zealand. The company is led by founder Himanshu H. Shah (Executive Chairman) and Shalin Shah (CEO), with Amit Shah as COO and Om Dhingra as Vice Chairman, and operates with 11-50 employees.

Marius Pharmaceuticals firmographics

Firmographics
Name
Marius Pharmaceuticals
Legal name
Marius Pharmaceuticals, LLC
Website
https://mariuspharma.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Marius Pharmaceuticals is a Raleigh-based specialty biopharmaceutical company that develops and commercializes KYZATREX, the first FDA-approved oral testosterone undecanoate therapy, selling primarily direct-to-consumer at ~$170/month and through telehealth and specialty pharmacy partners to men with hypogonadism.
Ownership category
akta.pro rank

Marius Pharmaceuticals industry classification

Industry
Product category
Testosterone Replacement Therapy
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Testosterone replacement therapy
  • Oral testosterone medication
  • Men's hormone therapy
  • Biopharmaceutical products
  • FDA-approved pharmaceuticals

Where Marius Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Raleigh
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Marius Pharmaceuticals business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Others

Revenue model

  1. Pharmaceutical Product Sales: Direct-to-consumer and partner-distributed sales of KYZATREX prescription medication. Launched in 2023 as a direct-to-consumer product without insurance coverage at approximately $170 per month.
  2. Licensing and Distribution Partnerships: International licensing agreements such as the Hikma Pharmaceuticals licensing agreement for Canadian market and regional partnerships for global expansion.
  3. International Early Access Program: Partnership with Smartway Pharmaceuticals for exclusive Early Access Provider arrangement in all countries outside the USA.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyMonthly prescription at approximately $170 per month

Go-to-market motion3 records

Distribution channels9 records

Marketing channels8 records

Marius Pharmaceuticals product offering

Product offering

Core offering

Marius Pharmaceuticals develops and sells KYZATREX (testosterone undecanoate), an FDA-approved oral testosterone replacement therapy in softgel capsule form for adult men with low or no testosterone due to certain medical conditions. The proprietary formulation is absorbed via the lymphatic system to bypass first-pass liver metabolism and is administered twice daily in 100mg, 150mg, and 200mg dosages. The company also distributes the product through telehealth partnerships, retail health channels, specialty pharmacies, and international licensing agreements.

Product overview

Marius Pharmaceuticals is a specialty pharmaceutical company focused on testosterone replacement therapy. The company's primary product is KYZATREX (testosterone undecanoate), an FDA-approved oral softgel capsule TRT launched in August 2022. The company operates alongside ReThink Testosterone, a companion disease-state awareness initiative that educates patients about testosterone deficiency and treatment options. The company has expanded internationally with Health Canada approval and is pursuing AI-native capabilities through Marius AI.

Differentiator

Problem solved

Functional benefit

Brands

  • KYZATREX: FDA-approved oral testosterone replacement therapy (testosterone undecanoate) CIII capsules for adult men with low testosterone levels.
  • ReThink Testosterone

Products and services

  • KYZATREX (testosterone undecanoate) KYZATREX is an FDA-approved oral testosterone replacement therapy (TRT) in softgel capsule form, absorbed primarily via the lymphatic system to avoid liver toxicity. It is indicated for adult men with low or no testosterone due to certain medical conditions, administered twice daily with food in 100mg, 150mg, and 200mg dosages.
  • Marius AI Marius AI is an AI-native pharmaceutical initiative launched by Marius Pharmaceuticals, positioning the company as the first AI-native pharmaceutical company.

Quantifiable outcome

  • 88-96% of patients achieved normal testosterone levels at Day 90
  • +4 more outcomes

Companies that use Marius Pharmaceuticals

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Marius Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Marius Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and minor.

  • Hikma PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 5 May 2026Licensing agreement for KYZATREX (testosterone undecanoate) CIII capsules in Canada. Enables Marius to expand market beyond the United States following Health Canada approval.
  • FDA Expert PanelcoreOthers · 4 December 2025CEO Shalin Shah invited to speak at landmark FDA Expert Panel on Testosterone Replacement Therapy for Men scheduled December 10, 2025. Significant regulatory engagement driving labeling updates.
  • All-Female Advisory Board (Women's Health)minorStrategic or Co-development Partner · 5 November 2025Formation of all-female advisory board including medical experts in urology, gynecology, longevity, and regenerative medicine to guide testosterone research for women, especially post-menopause.
  • Hims & Hers Health, Inc.coreGTM or Marketing Partner · 10 September 2025Marius Pharmaceuticals and Hims & Hers collaboration to expand access to KYZATREX, the first FDA-approved oral testosterone therapy offered on the Hims & Hers platform. This partnership enables direct-to-consumer access through the Hims & Hers telehealth platform serving nearly 2.5 million subscribers.
  • Major Academic Medical CenterminorStrategic or Co-development Partner · 3 March 2025Partnership with major academic medical center on education and research efforts for oral testosterone, supporting clinical development and medical education.
  • US Specialists Management, LLC (USSM)minorChannel Partner/ Reseller/ Distributor · 14 January 2025Partnership with USSM through affiliated urologic in-office dispensaries, expanding specialty pharmacy distribution network.
  • Gameday Men's HealthminorChannel Partner/ Reseller/ Distributor · 3 December 2024Distribution expansion collaboration with Gameday Men's Health, providing access through their men's health clinic network.
  • nuBioAge and nuHxminorStrategic or Co-development Partner · 25 September 2024Collaborative GLP-1 comparison study in male patients. Partnership to study KYZATREX's ability to prevent muscle loss from Wegovy ( GLP-1 medications) with 40% of weight loss being lean muscle.
  • NumanminorChannel Partner/ Reseller/ Distributor · 18 September 2024Partnership with UK-based Numan to combat testosterone deficiency with KYZATREX. Expands access to men in the UK market.
  • The Vitamin ShoppecoreChannel Partner/ Reseller/ Distributor · 3 September 2024Partnership to offer KYZATREX through The Vitamin Shoppe's Whole Health Rx telehealth platform powered by WellSync. Expands access to millions of American men experiencing testosterone deficiency through retail wellness channel.
  • WellSynccoreTechnology or Integration · 3 September 2024Technology partner powering The Vitamin Shoppe's Whole Health Rx telehealth platform. Provides virtual care platform connecting patients with licensed healthcare providers in real time.
  • Smartway PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 10 August 2023Smartway appointed as exclusive Early Access Provider for KYZATREX in all countries outside the USA. Smartway provides early access, compassionate use, and named patient supply services with hubs across UK, EU, Middle East, USA, and India.

Scale indicators6 records

Recent moves8 records

Expansion highlights8 records

Marius Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Antares Pharma: Antares (now part of Halozyme) developed Tlando, an oral testosterone undecanoate product directly competing with KYZATREX in the same oral TRT category. Both companies target men with hypogonadism through similar regulatory pathways and compete for the same prescriber base.
  • Tolmar Pharmaceuticals: Tolmar commercializes Jatenzo, another FDA-approved oral testosterone undecanoate and the closest direct competitor to KYZATREX. Both products use lymphatic absorption to avoid liver toxicity and compete for oral TRT market share.
  • Clarus Therapeutics: Clarus Therapeutics developed Jatenzo (originally) and remains focused on oral testosterone therapies, directly competing with KYZATREX in the oral TRT space. Similar specialty pharma profile targeting hypogonadism.

Emerging players

  • Acerus Pharmaceuticals: Acerus markets Natesto, a nasal testosterone replacement therapy, competing with KYZATREX for the same hypogonadism patient population through a differentiated non-oral delivery route. Similar specialty men's health focus.

Broad incumbents

  • AbbVie (AndroGel): AbbVie markets AndroGel, the legacy topical testosterone gel that has historically dominated the TRT market. While not a direct oral competitor, it serves the same hypogonadism patients and represents the standard-of-care Marius is displacing.
  • Endo Pharmaceuticals: Endo markets Aveed (testosterone undecanoate injection), an injectable testosterone undecanoate product. Operates in the same testosterone replacement therapy market and competes for the same hypogonadism patient base.
  • Upsher-Smith Laboratories: Upsher-Smith markets Testim, a topical testosterone gel competing for hypogonadism patients. Specialty pharma with overlapping men's health franchise and similar commercial-stage profile.

Regional players

  • Besins Healthcare: Besins manufactures AndroGel outside the US and other testosterone products globally, including in Europe and Asia. Comparable hormone therapy specialty pharma that Marius could eventually partner with or compete against in international markets.

Others

  • Hims & Hers Health: Hims & Hers is both a partner and adjacent player; it offers competing men's health treatments including branded and generic testosterone therapies through its telehealth platform. Comparable as a DTC men's health channel rather than a direct therapeutic competitor.
  • Hikma Pharmaceuticals: Hikma is the Canadian licensing partner for KYZATREX and a broad specialty/generic pharmaceutical company with overlapping men's health and endocrinology portfolios. Comparable as a specialty pharma distributor and adjacent therapeutic category player.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks1 record

Key highlights7 records

Customer concentration

Marius Pharmaceuticals social profiles

Digital presence

Marius Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Marius Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles12 records

Marius Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Marius Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marius Pharmaceuticals

What does Marius Pharmaceuticals do?

Marius Pharmaceuticals develops and sells KYZATREX (testosterone undecanoate), an FDA-approved oral testosterone replacement therapy in softgel capsule form for adult men with low or no testosterone due to certain medical conditions. The proprietary formulation is absorbed via the lymphatic system to bypass first-pass liver metabolism and is administered twice daily in 100mg, 150mg, and 200mg dosages. The company also distributes the product through telehealth partnerships, retail health channels, specialty pharmacies, and international licensing agreements.

Is Marius Pharmaceuticals a public or private company?

Marius Pharmaceuticals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Marius Pharmaceuticals founded?

Marius Pharmaceuticals was founded in 2015. It employs 11 to 50 people.

Where is Marius Pharmaceuticals based?

Marius Pharmaceuticals is headquartered in Raleigh, United States, in the North America region.

How does Marius Pharmaceuticals make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Distribution Partnerships and international Early Access Program.

Who are Marius Pharmaceuticals's main competitors?

Direct peers on record are Antares Pharma, Tolmar Pharmaceuticals and Clarus Therapeutics. Acerus Pharmaceuticals is listed as an emerging player. Broad incumbents are AbbVie (AndroGel), Endo Pharmaceuticals and Upsher-Smith Laboratories. Besins Healthcare is listed as a regional player. Others are Hims & Hers Health and Hikma Pharmaceuticals.

Does Marius Pharmaceuticals have an API?

No public API is recorded for Marius Pharmaceuticals.

What industry is Marius Pharmaceuticals in?

Marius Pharmaceuticals's product category is Testosterone Replacement Therapy. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireJosh Duhamel, Dr. Gabrielle Lyon Join Generation Iron Documentary ‘Longevity Code: The Truth About Testosterone’Generation Iron announced 'Longevity Code: The Truth About Testosterone,' a documentary directed by Vlad Yudin examining testosterone therapy's science, controversies, and future. It features experts like Josh Duhamel and Dr. Gabrielle Lyon, and explores FDA actions and women's health applications. The film is in production with a 2027 release expected.Urology TimesApproval sought for testosterone undecanoate in CanadaMarius Pharmaceuticals has submitted a new drug application to Health Canada for Kyzatrex, an oral testosterone replacement therapy, with a regulatory decision expected in the second quarter of 2025. If approved, this would mark the first oral testosterone therapy available in the Canadian market. The submission follows US FDA approval in July 2022, supported by clinical trial data demonstrating efficacy and safety in treating male hypogonadism.Urology TimesStudy initiated to explore effect of oral TRT on spermatogenesisMarius Pharmaceuticals announced the initiation of a pilot study to evaluate the effect of its oral testosterone replacement therapy, Kyzatrex, on spermatogenesis in men with hypogonadism. The study aims to enroll 20 patients and will assess changes in sperm count and hormone levels over three months to determine if this oral formulation preserves fertility compared to traditional TRT methods.Urology TimesTrial to assess testosterone undecanoate in older men with hypogonadismMarius Pharmaceuticals has initiated a postmarketing study to evaluate testosterone undecanoate (Kyzatrex) for potential label expansion in men aged 65 to 80 with hypogonadism. The six-month, single-site trial will enroll 50 participants to assess quality of life and health markers while comparing the current titration protocol against a simplified once-daily dosing regimen. This development aims to support broader clinical utility of the drug for an older patient demographic.The American Bazaar -Marius Pharmaceuticals backs FDA proposal to revise testosterone therapy warningsMarius Pharmaceuticals has publicly supported the FDA's proposal to update prescribing information for testosterone replacement therapies, specifically seeking to remove language regarding unestablished safety for age-related low testosterone. This regulatory shift follows a review of clinical evidence, including a cardiovascular outcomes study of over 5,200 men that showed no significant increase in serious cardiovascular events. The proposed changes also aim to revise warnings related to prostate cancer and enlarged prostate conditions.GlobeNewswireMarius Pharmaceuticals Applauds FDA’s Proposed Testosterone Labeling Updates as a Turning Point for Men’s HealthThe FDA announced proposed updates to testosterone replacement therapy labeling that would remove limitations on use for age-related low testosterone and revise prostate health warnings, based on new clinical evidence including a cardiovascular outcomes trial of over 5,200 men. This marks the second major FDA labeling update for testosterone products in 16 months, following February 2025 removal of the cardiovascular boxed warning. Marius Pharmaceuticals, which petitioned the FDA in September 2024 and whose CEO Shalin Shah served as an invited speaker at the agency's expert panel, called the development a defining moment for evidence-based men's health.BioSpaceMarius Pharmaceuticals Applauds FDA’s Proposed Testosterone Labeling Updates as a Turning Point for Men’s HealthThe FDA requested updates to testosterone replacement therapy labeling, removing the limitation of use for age-related low testosterone and revising prostate-related warnings. The agency cited a cardiovascular outcomes trial of over 5,200 men finding no meaningful increase in major adverse events. Marius CEO Shalin Shah called it a defining moment for evidence-based men's health.GlobeNewswireNew Research from Marius Pharmaceuticals Reveals Major Men's Health Awareness Gap: 65% Have Never Had Their Testosterone Levels TestedA Marius Pharmaceuticals survey of 1,003 U.S. men ages 40-65 found 65% have never had their testosterone levels tested, despite 75% reporting at least one symptom of deficiency. The survey also found 42% delayed or avoided medical care, and 45% said health concerns impacted work, relationships, or daily responsibilities.BioSpaceMarius Pharmaceuticals Announces Key Leadership Expansion and Launch of Marius AI, Positioning the Company as the First AI-Native Pharmaceutical CompanyMarius Pharmaceuticals announced the appointment of Greg Thomas as SVP of Marketing and Justin Edelman to lead its new Marius AI division, positioning the company as the first AI-native pharmaceutical firm. The AI initiative integrates artificial intelligence across operations, including sales, marketing, and regulatory functions. The company also added Dr. Bithika M. Thompson as an advisor.GlobeNewswireMarius Pharmaceuticals Announces Key Leadership Expansion and Launch of Marius AI, Positioning the Company as the First AI-Native Pharmaceutical CompanyMarius Pharmaceuticals announced the appointment of Greg Thomas as SVP of Marketing and Justin Edelman to lead its new Marius AI division, positioning the company as the first AI-native pharmaceutical firm. The AI initiative integrates artificial intelligence across operations, including sales, marketing, and regulatory functions. The company also added Dr. Bithika M. Thompson as an advisor.